Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Pink

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Radiation Research|July 16, 2011
Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancersCharles A Kunos, Gina Ferris, Natalie Pyatka, et al.
Radiation Research|November 26, 2009
Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 proteinCharles A Kunos, Song-mao Chiu, John Pink, et al.
International Journal of Radiation Oncology, Biology, Physics|April 8, 2011
Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose ratesCharles A Kunos, Valdir C Colussi, John Pink, et al.
Plos One|September 9, 2014
Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancerGary Wildey, Yanwen Chen, Ian Lent, et al.
Angewandte Chemie (International Ed. in English)|November 24, 2004
cRGD-functionalized polymer micelles for targeted doxorubicin deliveryNorased Nasongkla, Xintao Shuai, Hua Ai, et al.
Radiation Research|October 20, 2010
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancersCharles A Kunos, Tomas Radivoyevitch, John Pink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancerCharles A Kunos, Steven Waggoner, Vivian von Gruenigen, et al.
Cancers|December 4, 2012
dNTP Supply Gene Expression Patterns after P53 LossTomas Radivoyevitch, Yogen Saunthararajah, John Pink, et al.
Cancer Medicine|March 23, 2023
Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIVYulan Qing, Ricky Chan, Pingfu Fu, et al.
Molecular Cancer Therapeutics|July 17, 2014
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerJosephine Kam Tai Dermawan, Katerina Gurova, John Pink, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Radiation Research|July 16, 2011
Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancersCharles A Kunos, Gina Ferris, Natalie Pyatka, et al.
Radiation Research|November 26, 2009
Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 proteinCharles A Kunos, Song-mao Chiu, John Pink, et al.
International Journal of Radiation Oncology, Biology, Physics|April 8, 2011
Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose ratesCharles A Kunos, Valdir C Colussi, John Pink, et al.
Plos One|September 9, 2014
Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancerGary Wildey, Yanwen Chen, Ian Lent, et al.
Angewandte Chemie (International Ed. in English)|November 24, 2004
cRGD-functionalized polymer micelles for targeted doxorubicin deliveryNorased Nasongkla, Xintao Shuai, Hua Ai, et al.
Radiation Research|October 20, 2010
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancersCharles A Kunos, Tomas Radivoyevitch, John Pink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancerCharles A Kunos, Steven Waggoner, Vivian von Gruenigen, et al.
Cancers|December 4, 2012
dNTP Supply Gene Expression Patterns after P53 LossTomas Radivoyevitch, Yogen Saunthararajah, John Pink, et al.
Cancer Medicine|March 23, 2023
Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIVYulan Qing, Ricky Chan, Pingfu Fu, et al.
Molecular Cancer Therapeutics|July 17, 2014
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancerJosephine Kam Tai Dermawan, Katerina Gurova, John Pink, et al.
Pageof 2